CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired SAMDI Tech, Inc. for $62.8 million (net of $0.4 million cash, inclusive of a previously owned 20% interest valued at $12.6 million), a transaction completed in January 2023, structured as cash.
SAMDI Tech, Inc. operates in DSA. Provider of a label-free high-throughput screening mass spectrometry (HTS MS) platform for drug discovery.
Added a label-free HTS MS drug-discovery platform to Charles River's DSA solutions portfolio.
Advisory firms were not disclosed for this transaction.